Aligos Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.8M | $169.0K | $741.0K | $965.0K | $311.0K | $606.0K | $1.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $24.1M | $23.4M | $17.0M | $23.9M | $14.0M | $14.5M | $16.0M | $16.8M |
| SG&A Expense | $5.6M | $6.4M | $4.9M | $5.2M | $5.6M | $5.1M | $5.2M | $4.6M |
| Operating Income | $-1.9M | $-26.9M | $-21.8M | $-28.4M | $-18.6M | $-19.2M | $-20.6M | $-20.1M |
| Operating Margin | — | -951.6% | -12,907.7% | -3,827.4% | -1,924.0% | -6,187.5% | -3,393.2% | -1,610.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.3M | $-22.7M | $-19.9M | $-31.5M | $-15.7M | $43.1M | $-82.1M | $-19.2M |
| Income Tax Expense | $2.8M | $317.0K | $30.0K | $56.0K | $185.0K | $43.0K | $27.0K | $91.0K |
| Net Income | $-1.5M | $-23.0M | $-19.9M | $-31.5M | $-15.9M | $43.1M | $-82.2M | $-19.3M |
| Net Margin | — | -814.1% | -11,763.9% | -4,256.0% | -1,643.8% | 13,854.7% | -13,556.1% | -1,540.7% |
| EPS (Basic) | $-0.14 | $-2.21 | $-3.00 | $-3.04 | $-1.53 | $5.12 | $-13.10 | $-1.54 |
| EPS (Diluted) | $-0.14 | $-2.21 | $4.23 | $-3.04 | $-1.53 | $-2.11 | $-13.10 | $-1.54 |
| Shares Outstanding (Basic) | 10.4M | 10.4M | 9.9M | 10.4M | 10.4M | 8.4M | 6.3M | 12.5M |
| Shares Outstanding (Diluted) | 10.4M | 10.4M | 9.9M | 10.4M | 10.4M | 8.7M | 6.3M | 12.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |